Female Epidemiology of Transcription-Mediated Amplification-Based Trichomonas vaginalis Detection in a Metropolitan Setting with a High Prevalence of Sexually Transmitted Infection

ABSTRACT Recent literature has reported increased accuracy of Trichomonas vaginalis transcription-mediated amplification (TMA)-based analyte-specific reagent (ASR) testing in female populations. A retrospective investigation assessed 7,277 female first-void urine, cervical, or vaginal specimens submitted from a high-prevalence sexually transmitted infection (STI) community to characterize prevalence of disease etiologies. The most common STI phenotype reflected detection of solely T. vaginalis (54.2% of all health care encounters that resulted in STI detection). In females with detectable T. vaginalis, codetection of Chlamydia trachomatis and Neisseria gonorrhoeae occurred in 7.8% and 2.7% of health care encounters, respectively. The mean age of women with detectable T. vaginalis (30.6) was significantly higher than those for women with C. trachomatis or N. gonorrhoeae (22.3 and 21.6, respectively; P < 0.0001). T. vaginalis was the predominant sexually transmitted agent in women over the age of 20 (P < 0.0002). C. trachomatis was the most commonly detected agent in females under the age of 21, particularly from cervical specimens. However, first-void urine detection rates for T. vaginalis and C. trachomatis within this age demographic demonstrated no difference (P = 0.92). While overall and cervical specimen-derived detection of T. vaginalis within African American majority geographical locales outweighed that within majority Caucasian geographical regions (P ≤ 0.004), this difference was not noted with first-void urine screening (P = 0.54). Health care professionals can consider TMA-based T. vaginalis screening for a wide age range of patients; incorporation of first-void urine specimens into screening algorithms can potentiate novel insight into the epidemiology of trichomoniasis.

[1]  Jeanne E. Hryciuk,et al.  Assessment of screening practices in a subacute clinical setting following introduction of Trichomonas vaginalis nucleic acid amplification testing. , 2012, WMJ : official publication of the State Medical Society of Wisconsin.

[2]  K. Chapin,et al.  Prevalence of Trichomonas vaginalis and Coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as Determined by the Aptima Trichomonas vaginalis Nucleic Acid Amplification Assay , 2012, Journal of Clinical Microbiology.

[3]  Jeanne E. Hryciuk,et al.  Three-Year History of Transcription-Mediated Amplification-Based Trichomonas vaginalis Analyte-Specific Reagent Testing in a Subacute Care Patient Population , 2011, Journal of Clinical Microbiology.

[4]  C. Gaydos,et al.  Molecular Testing for Trichomonas vaginalis in Women: Results from a Prospective U.S. Clinical Trial , 2011, Journal of Clinical Microbiology.

[5]  K. Chapin,et al.  Comparison of Aptima Trichomonas vaginalis Transcription-Mediated Amplification Assay and BD Affirm VPIII for Detection of T. vaginalis in Symptomatic Women: Performance Parameters and Epidemiological Implications , 2011, Journal of Clinical Microbiology.

[6]  Jeanne E. Hryciuk,et al.  Trichomonas vaginalis transcription-mediated amplification-based analyte-specific reagent and alternative target testing of primary clinical vaginal saline suspensions. , 2010, Diagnostic microbiology and infectious disease.

[7]  Elizabeth A. Hesse,et al.  Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians , 2010, Sexually Transmitted Infections.

[8]  E. Munson,et al.  Molecular diagnosis of Neisseria gonorrhoeae infection in the United States. , 2009, Expert opinion on medical diagnostics.

[9]  J. Schwebke,et al.  Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. , 2009, American journal of obstetrics and gynecology.

[10]  T. Farley,et al.  Trichomonas Vaginalis Treatment Reduces Vaginal HIV-1 Shedding , 2009, Sexually transmitted diseases.

[11]  Jeanne E. Hryciuk,et al.  Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence , 2008, Journal of Clinical Microbiology.

[12]  G. Mcquillan,et al.  The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Joan M. Chow,et al.  Detection of Chlamydia trachomatis by Nucleic Acid Amplification Testing: Our Evaluation Suggests that CDC-Recommended Approaches for Confirmatory Testing Are Ill-Advised , 2006, Journal of Clinical Microbiology.

[14]  E. Portillo,et al.  High Analytical Sensitivity and Low Rates of Inhibition May Contribute to Detection of Chlamydia trachomatis in Significantly More Women by the APTIMA Combo 2 Assay , 2006, Journal of Clinical Microbiology.

[15]  M. Handcock,et al.  The Prevalence of Trichomoniasis in Young Adults in the United States , 2005, Sexually transmitted diseases.

[16]  W. Secor,et al.  Trichomonas vaginalis-Induced Epithelial Monolayer Disruption and Human Immunodeficiency Virus Type 1 (HIV-1) Replication: Implications for the Sexual Transmission of HIV-1 , 2005, Infection and Immunity.

[17]  A. Nagayama,et al.  In vitro assessment of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis using highly purified elementary bodies. , 2005, Journal of medical microbiology.

[18]  Jill S. Huppert,et al.  Use of an Immunochromatographic Assay for Rapid Detection of Trichomonas vaginalis in Vaginal Specimens , 2005, Journal of Clinical Microbiology.

[19]  S. Pinkerton,et al.  Estimates of the Annual Number and Cost of New HIV Infections Among Women Attributable to Trichomoniasis in the United States , 2004, Sexually transmitted diseases.

[20]  Stuart Berman,et al.  Perspectives on Sexual and Reproductive Health Sexually Transmitted Diseases among American Youth: Incidence and Prevalence Estimates, 2000 , 2022 .

[21]  J. Schwebke,et al.  High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management. , 2003, The Journal of infectious diseases.

[22]  T. Quinn,et al.  Performance of the APTIMA Combo 2 Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Female Urine and Endocervical Swab Specimens , 2003, Journal of Clinical Microbiology.

[23]  P. Kerndt,et al.  Trichomonas vaginalis, HIV, and African-Americans. , 2001, Emerging infectious diseases.

[24]  W. Miller,et al.  Trichomonas vaginalis as a cause of urethritis in Malawian men. , 1999, Sexually transmitted diseases.

[25]  M. Krohn,et al.  Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery , 1997, Sexually transmitted diseases.

[26]  J. Mcgregor,et al.  Trichomonas Vaginalis: A Reemerging Pathogen , 1993, Clinical obstetrics and gynecology.

[27]  C. Schofield Sexually transmitted disease surveillance. , 1982, British medical journal.